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This review is a comprehensive analysis of the progress made so far on the delivery of 
polynucleotide-based therapeutics to the eye, using synthetic nanocarriers. Attention has been 
addressed to the capacity of different nanocarriers for the specific delivery of polynucleotides to 
both, the anterior and posterior segments of the eye, with emphasis on their ability to (i) 
improve the transport of polynucleotides across the different eye barriers; (ii) promote their 
intracellular penetration into the target cells; (iii) protect them against degradation and, (iv) 
deliver them in a long-term fashion way. Overall, the conclusion is that despite the advantages 
that nanotechnology may offer to the area of ocular polynucleotide-based therapies (especially 
AS-ODN and siRNA delivery), the knowledge disclosed so far is still limited. This fact 
underlines the necessity of more fundamental and product-oriented research for making the way 
of the said nanotherapies towards clinical translation.  
 
Keywords: polynucleotides; nanocarriers; ocular polynucleotide delivery; anterior segment; 
posterior segment; eye. 
 
1. Introduction  
According to the World Health Organization (WHO), 285 million individuals (4.25% of the 
world’s population) suffered from visual impairment in 2010, of which 246 million had low 
vision and 39 million were blind (Pascolini and Mariotti, 2011). Furthermore, it is predicted that 
by 2020, 76 million individuals will presumably suffer from blindness mainly due to cataract, 
glaucoma and age-related macular degeneration (AMD) (Pizzarello et al., 2004). This scenario 
underlines the necessity of more innovative and effective ocular therapy strategies. Nowadays 
approaches based on polynucleotide ocular delivery hold great promise since they may alter 
gene expression without affecting the structure and sequence of the gene.  
The eye is an attractive organ for the development of polynucleotide-based therapies due to the 
fact that the target tissues are accessible without the need of systemic administration. However, 
apart from this, the eye is protected by extraordinary barriers, which are very difficult to 
circumvent, especially in the case of hydrophilic and high molecular weight molecules such as 
polynucleotides. These barriers are illustrated in Fig. 1, and are briefly described as follows: 
In the anterior segment, the first barrier encountered by topically applied molecules is the tear 
film that is composed of three layers consisting of lipid, aqueous fluid and mucus layers. The 
presence of different enzymes and mucins in the tear film as well as its constant turnover protect 
















surface mucins and covers the surface of the corneal and conjunctival epithelia (Spurr-Michaud 
et al., 2007). The corneal barrier consists of a transparent and avascular multiple layer 
epithelium, a collagenous layer (stroma) and an internal endothelium. The corneal epithelium 
continues with the conjunctiva, a transparent and vascularized epithelial membrane that contains 
goblet cells which are responsible for the production of the mucin MUC5AC (Ruponen and 
Urtti, 2015). In addition, the presence of tight junctions in both tissues constitutes an obstacle 
for permeation of drugs, especially through the cornea (Yoshida et al., 2009). The aqueous 
humor is also part of the anterior segment and it is mostly composed of water and electrolytes, 
low molecular weight compounds and proteins (de Berardinis et al., 1965; Tripathi et al., 1989). 
 
Fig. 1 Representation of the structure of human eye (in more detail the tear film, cornea, 
conjunctiva, vitreous humor and retina) and some examples of diseases affecting both anterior 
and posterior segments. 
 
The posterior segment is protected by the sclera, which represents the continuation of the 
cornea, and it is formed by the vitreous humor, retina, choroid and optical nerve. The vitreous 
humor is a highly dense matrix mainly composed of collagen, hyaluronic acid (HA) and also 
proteoglycans that contain negatively charged glycosaminoglycans (GAGs), that can hinder the 
diffusion of drugs to the retina, even when they are directly injected into this compartment 
(Peeters et al., 2005). However, it can also serve as a reservoir for the sustained release of drugs 
(Bourges et al., 2003). The retina encompasses different cell layers consisting mainly of nerve 
cells (ganglion cell layer (GCL)), photoreceptors and retinal pigment epithelium (RPE).  
Both the anterior and posterior segments are also protected by blood-barriers, the blood-aqueous 
and the blood-retinal barriers, respectively. The blood-aqueous barrier contains the uveal 
endothelium and ciliary epithelium. This barrier restricts the access of compounds such as 
plasma albumin and hydrophilic drugs into the aqueous humor, but it is also responsible for the 
passage of nutrients essential for corneal function (del Amo and Urtti, 2008). The inner and 
outer blood-retinal barrier is formed by the retinal vessels’ endothelial cells and the retinal 
pigment epithelium cells, respectively. In both parts of the blood-retinal barrier, the constituent 
cells are connected by tight junctions. This barrier plays a fundamental role in the regulation of 
nutrients flux and the restriction of drug diffusion into and out of the retina (Mannermaa et al., 
2006). 
There are several routes intended to reach either the anterior or posterior segments of the eye. 
















anterior segment whereas intravitreal (IVT) and subretinal injections are the most common 
methods used for the treatment of relevant diseases that affect the back of the eye.  
In the next sections we will comparatively analyze the nanotechnology-based strategies that 
have been reported so far to deliver polynucleotides to both the anterior and posterior segments 
of the eye. We will highlight their potential for targeting specific tissues and thus, for the 
treatment of specific ocular diseases. We will conclude with a perspective of the challenges that 
need to be overcome for the clinical translation and industrial development of these 
nanomedicines. 
 
2. Polynucleotides used for the treatment of ocular diseases 
The polynucleotides that have been studied until now as potential treatments for ocular 
disorders are described below. 
Plamid DNA (pDNA)  
Plasmid DNA-therapeutics aims to express a specific therapeutic gene. Therefore, the plasmid 
needs to be internalized into the nucleus of the cell (which is still a challenge) where it will be 
transcripted into a messenger RNA (mRNA). Thereafter, the newly formed mRNA is 
transported into the cytoplasm where it is translated into the codified protein. The first 
nucleotide-based therapy reaching clinical trials was a pDNA construct proposed for the 
treatment of an immunodeficiency disease caused by an adenosine deaminase deficiency 
(Blaese et al., 1995). Since then, according to the clinical trials database (clinicaltrials.gov), 
several pDNA clinical trials have been conducted although only three of them have been 
oriented to the treatment of ocular diseases focusing on intraocular melanoma and allergic 
rhinoconjunctivitis. 
Antisense oligonucleotides (AS-ODNs) 
AS-ODNs are synthetic single-stranded RNA fragments (13 to 25 nucleotides) firstly described 
in 1978 (Stephenson and Zamecnik, 1978), that bind to complementary intracellular mRNA 
strands by base pairing, forming a short double helix and ultimately blocking its transcription 
into the undesirable protein. AS-ODNs can also modulate gene expression by enzymatic 
degradation of targeted mRNA by ribonuclease H (Walder and Walder, 1988). The activity of 
AS-ODNs is highly limited due to their poor intracellular uptake and poor stability in biological 
fluids (Opalinska and Gewirtz, 2002). 
The only AS-ODNs-based drug (without the association to any type of carrier) approved by the 
FDA for an ocular condition was registered in 1998. This nucleic-acid based drug, fomivirsen, 
was marketed as Vitravene

















immunocompromised patients (Crooke, 1998). However, in 2004 Novartis Ophtalmics 
discontinued the product due to the significant decrease of Vitravene

 sales as a consequence of 
the low number of patients infected with CMV. Other AS-ODNs are currently under clinical 
trials for the treatment of different ocular diseases (see Table 1). For instance, aganirsen (GS-
101) has completed a phase III clinical trial for the topical treatment of corneal 
neovascularization and it is currently in phase II for the treatment of AMD, neovascular 
glaucoma, retinopathy of prematurity and diabetic macular edema.  
Small interfering RNA (siRNA) 
RNAi-based technology, namely siRNA is a promising alternative for treating eye diseases 
affecting both, the anterior and posterior segments of the eye. This is a double-stranded RNA 
(dsRNA) of 21-23 base pairs designed to specifically knockdown target genes (Elbashir et al., 
2001). Unlike pDNA, this type of polynucleotide only needs to get into the cytoplasm of the cell 
where it is loaded into the RNA-induced silencing complex (RISC) (Hammond et al., 2000).  
The first clinical trial using a siRNA (Cand5) was conducted in 2004 for the treatment of wet 
AMD and, since then, other clinical trials based on siRNA have been performed for ocular 
therapies such as Sirna-027 for choroidal neovascularization (CNV), PF-04523655 for diabetic 
retinopathy, SYL1001 for dry eye and SYL040012 and QPI-1007 for glaucoma (see Table 1). 
Moreover, several siRNA therapies are under preclinical development for corneal 
neovascularization (corneal NV), retinitis pigmentosa, diabetic retinopathy, and fibrotic eye 
disease, among others. Nonetheless, the majority of the undergoing siRNA studies target 
diseases affecting the retina. 
As other polynucleotides, siRNA also suffers from poor stability in biological fluids and 
restricted capacity to enter cells. Different chemical modifications have been performed in the 
structure of polynucleotides especially to ameliorate their stability when in contact with biologic 
fluids thus, improving their bioavailability (Beigelman et al., 1995; Beverly et al., 2006; Chiu 
and Rana, 2003; Epstein and Kurz, 2007; Hall et al., 2004).  
Aptamers 
Aptamers are small molecules synthesized from DNA or RNA sequences that have the capacity 
to bind to specific proteins, as well as to nucleic acids and other compounds. Due to their unique 
three-dimensional structure they may act in a similar way as antibodies do but with the 
advantages of being non-immunogenic and highly stable molecules (Chandola et al., 2016). The 
only aptamer that has received marketing approval, in 2004, for ocular administration is 
Pegaptanib sodium (Macugen

), which is an RNA-based aptamer directed against vascular 
















known as pegpleranib (Fovista

) and ARC1905 (Zimura

) that are under clinical trial for the 
treatment of AMD (Table 1).  
 
Table 1. Products under clinical development for both the anterior and posterior segments of the 
eye 
 
3. Synthetic nanocarriers for the delivery of polynucleotides to the eye 
In general, the delivery of polynucleotides has been attempted using viral vectors (adenovirus 
(Ads), adeno-associated virus (AAVs), lentivirus, and retrovirus) and non-viral carriers (e.g. 
nanoparticles, liposomes, dendrimers, nanoemulsions, micelles, etc.). Currently, there are 
already some approved gene therapy products using viral vectors. These products include a 
recombinant Ads-p53 gene therapy for the treatment of head and neck squamous cell carcinoma 
(Gendicine
®
) (Pearson et al., 2004), an oncolytic virus that promotes cytotoxicity in cancer cells 
for nasopharyngeal cancer (Oncorine
®
), a retroviral vector loaded with a human cytocidal cyclin 
G1 construct for the treatment of solid tumors (Rexin-G
®
) (Gordon and Hall, 2010) and an 
AAV1 delivering a human lipoprotein lipase (LPL) variant for the treatment of LPL deficiency 
(Glybera
®





), the Philippines (Rexin-G
®
) and Europe (Glybera
®
), major concerns 
associated to their immunogenic and mutagenic risks remain (Thomas et al., 2003). These 
concerns have motivated the search of synthetic delivery systems, which are safer and easier to 
produce in large scale. 
Currently, there are a few ocular nanotechnology-based products on the market, that include a 







), and liposomes (Lipomil
®
), as well as 
drug-containing nanomedicines, such as cyclosporin-A nanoemulsion (Restasis
®
), indicated for 
severe DES, a difluprednate nanoemulsion (Durezol
®
) indicated for the treatment of ocular 
inflammation, verteporfin liposomes (Visudyne
®
), a photodynamic therapy and pegaptanib 
(Macugen
®
), a PEGylated anti-VEGF, both approved for the treatment of AMD. Despite of this, 
the development of synthetic nanocarriers for the delivery of polynucleotides to the eye is still 
in an early stage. This early development is illustrated in Fig. 2, whereby the number of research 
articles describing non-viral carriers for ocular polynucleotide therapy has been scarce until the 
last decade. An additional observation is that polymeric nanoparticles/nanocomplexes followed 
by liposomes have been the nanostructures that have received most of the attention up to now. 
















as described in the next section, the tendency is now being oriented towards RNA-based 
therapies.  
 
FIG. 2 Illustration of the evolution of the number of published research articles describing the 
use of non-viral carriers for ocular polynucleotides delivery from 1997 to 2016. Data obtained 
from Scopus. Search defined with the combination of keywords and or groups of keywords: 
[ocular, eye] and/or [pDNA, RNA, siRNA, antisense oligonucleotides, polynucleotides] and/or 
[nanoparticles, nanocomplexes, liposomes, lipoplexes, niosomes, micelles, nanoemulsions, 
nanocapsules, dendrimers]. Language: English. 
 
Fig. 4 illustrates non-viral delivery systems currently under development for ocular 
polynucleotide/drug delivery. Overall, the composition and characteristics of the nanocarriers 
currently under investigation are discussed below. 
Nanocomplexes and Nanoparticles 
The design of these non-viral carriers for polynucleotide delivery has evolved over time going 
from simple nanocomplexes of cationic polymers, e.g. polyethyleneimine (PEI), and 
polynucleotides (dos Santos et al., 2006a; dos Santos et al., 2006b; Ketola et al., 2013; Kuo et 
al., 2005) to more defined nanoparticles. These nanoparticles have been developed using an 
array of biomaterials which include hydrophobic and amphiphilic polyesters, such as 
poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLA-PEG) (Csaba et al., 
2005; Perez et al., 2001), which were investigated at first by our laboratory, as well as proteins 
such as gelatin (Xu et al., 2008), albumin (Arnedo et al., 2004), and cationic polymers, mainly 
poly-L-lysine (PLL) (Ketola et al., 2013; Männistö et al., 2002) and chitosan (Csaba et al., 
2009; de la Fuente et al., 2008a; de la Fuente et al., 2008b).  
Our group was among the pioneers in the development of nanoparticles for topical ocular drug 
delivery (Calvo et al., 1996; Calvo et al., 1994; Losa et al., 1991; Losa et al., 1993) and reported 
for the first time the potential of chitosan/hyaluronic acid nanoparticles for the delivery of 
polynucleotides, i.e. pDNA, to the eye (de la Fuente et al., 2008a; de la Fuente et al., 2008b). 
The inclusion of HA allowed a better retention and permeation through the rabbits’ corneal 
epithelium, which resulted in a more efficient transfection of the epithelial cells (de la Fuente et 
al., 2008a; de la Fuente et al., 2008b). The combination of different characteristics of these 
systems, such as biocompatibility, mucoadhesion and targeting of CD44 receptors make them 
suitable carriers for polynucleotide delivery to the cornea and conjunctiva. In a different study, 
















by shielding the positive charges and reducing non-specific interactions with cell membrane by 
the CD44 receptor targeting (Hornof et al., 2008).  
With regard to the properties that influence the interaction of nanoparticles with the corneal 
epithelium, we have found that, in addition to the size (Calvo et al., 1996), the surface 
composition of the nanoparticles and their charge play an important role in their interaction with 
the corneal epithelium. For example, we observed that chitosan nanoparticles have the ability to 
interact with the ocular mucosa and be internalized by the corneal epithelial cells (de Campos et 
al., 2004). Other authors have explored the functionalization of particles with specific targeting 
ligands, such as transferrin and arginine-glycine-aspartic acid (RGD), which are expected to 
improve nanoparticle uptake by ocular cells (Chen et al., 2013; Singh et al., 2009). 
Liposomes and lipoplexes  
As an alternative to polymers, cationic lipids such as 3-β[N-(N’,N’ imethylaminoethane)- 
carbamoyl] cholesterol (DC-cholesterol) and 1,2-Dioleoyl-3- trimethylammonium propane 
(DOTAP) (Jääskeläinen et al., 2000; Lajunen et al., 2014; Matsuo et al., 1996; Rajala et al., 
2014), have also been used to produce complexes with polynucleotides, named lipoplexes or 
liposomes. Cationic lipids, in addition to their capacity to complex polynucleotides, are 
supposed to help the liposomes interacting with the corneal epithelium (Jiang et al., 2012). 
Neutral lipids such as 1,2-dioleoyl-3- hosphatidylethanolamine (DOPE) have also been included 
in liposomal formulations as “helper” lipids since they can change the conformation of these 
systems to an inverted hexagonal organization thus facilitating their endocytosis and delivering 
the polynucleotide into the cytoplasm (Koltover et al., 1998; Smisterová et al., 2001). The 
surface modification of liposomes with polymers has also been studied as a way to enhance 
their stability, e.g. through PEGylation (Bochot et al., 2002; Chen et al., 2013; Liu et al., 2011) 
and to facilitate their internalization and transfection efficiency through the use of peptide 
penetration enhancers (Mannermaa et al., 2005; Rajala et al., 2014).  
Stimuli-responsive liposomes have also been developed. This is the case of the light-induced 
liposomal formulation containing verteporfin (Visudyne
®
), which has been marketed for the 
treatment of AMD. Due to the different laser applications in ophthalmology, and the time- and 
site-specific drug release from light-activated liposomes, these systems are of particular interest 
for the ocular field (Lajunen et al., 2016b). More specifically, indocyanine green-liposomes 
might be an attractive option for ocular drug delivery. Indocyanine green is an FDA approved 
imaging agent and the only one approved for clinical use under near infrered (NIR) light, which 
is less damaging that UV light. Moreover, a fast exposure of these light-activated liposomes to 


















FIG. 3 Illustration of the number of published research articles describing the use of non-viral 
carriers for ocular pDNA, siRNA and AS-ODN delivery from 1997 to 2016. Data obtained from 
Scopus. Search defined with the combination of keywords and or groups of keywords: [ocular, 
eye] and/or [pDNA, siRNA, antisense oligonucleotides] and/or [nanoparticles, nanocomplexes, 













 98 (Kaur et al., 2012; Saettone et al., 1996), which are known for their 
penetration enhancer capacity. Several niosome formulations have been developed for ocular 
drug delivery and some of them have shown promising results for ocular polynucleotide 
delivery (Ojeda et al., 2016; Puras et al., 2015; Puras et al., 2014). Still, as shown in Fig. 3, 
these carriers are the least common nanocarriers used for polynucleotide delivery to ocular 
tissues. 
Micelles  
Micelles comprise self-assembling diblock or multiblock amphiphilic molecules forming highly 
ordered monolayer structures. An example of a triblock copolymer micelle approved by the 
FDA for ophthalmic products is the micellar system formed by the copolymer poly(ethylene 
oxide)–poly(propylene oxide)–poly(ethylene oxide) (PEO–PPO–PEO) (Tong et al., 2007). This 
specific composition has been explored for the delivery of pDNA to different ocular tissues 
(Liaw et al., 2001; Tong et al., 2007).  
Nanoemulsions and Nanocapsules 
Nanoemulsions were evaluated in the early 90s by Benita’s group for topical ocular drug 
delivery (Muchtar et al., 1992), and a few years later they were suggested for AS-ODN delivery 
(Teixeira et al., 1999). More recently, Benita’s group evaluated cationic nanoemulsions which 
contain the surfactant DOTAP to enhance the carrier residence time on the ocular surface and 
efficiently deliver AS-ODNs to the retina (Hagigit et al., 2010; Hagigit et al., 2012).  
Nanocapsules share common features with nanoemulsions and polymer nanoparticles, as they 
are formed by oily nanodroplets surrounded by a polymer coating. Our group pioneered the 
development of nanocapsules for topical ocular drug delivery (Calvo et al., 1997; Losa et al., 
1993). Interestingly, working with PEGylated polyester nanocapsules we also observed that the 
















fluids and, this improved stability was translated into a greater transport of the nanocapsules 
across the corneal epithelium (de Campos et al., 2003). More recently, we have found that 
nanocapsules containing polyarginine and protamine arginine-rich polymer shells, have an 
improved ocular retention and can be used for corneal wound healing (Reimondez-Troitiño et 
al., 2016).  
 
FIG. 4 Representation of the structure of different types of nanocarriers. 
 
Solid lipid nanoparticles (SLN)  




 ATO 5, Gelucire
®
 44/14 
and stearylamine (del Pozo-Rodríguez et al., 2008; Li et al., 2008). These nanoparticles have 
been shown to facilitate drug penetration into the cornea (Cavalli et al., 2002; Li et al., 2008) 
and were used for the first time for ocular polynucleotide delivery in 2008 by del Pozo-
Rodriguez (del Pozo-Rodríguez et al., 2008). 
Dendrimers 
Dendrimers are tree-like branched structures that consist of an inner core, repetitive branched 
units (i.e. different generations) and peripheral multivalent functional groups, which play a key 
role in the complexation with polynucleotides. The use of PAMAM (Chaum et al., 1999; Hudde 
et al., 1999) and PLL (Marano et al., 2004) based dendrimers for ocular polynucleotide delivery 
was first reported in 1999 and 2004, respectively. Since then, only a few reports have described 
the use of these nanocarriers for oligonucleotide (Marano et al., 2004; Wimmer et al., 2002) and 
pDNA (Hudde et al., 1999) ocular delivery and none for siRNA. 
 
FIG. 5 Schematic representation of the main strategies used to develop nanocarriers aiming to 
treat different diseases affecting both anterior (A) and posterior eye segments (B). When 
targeting the anterior segment structures, the topically applied carriers usually present a positive 
surface charge and a mucoadhesive polymeric coating to increase the retention time in the 
ocular surface. They can also be PEGylated in order to be muco-penetrating and even include 
specific targeting moieties like arginine-glycine-aspartic acid sequences to target the desired 
tissue. When targeting the posterior eye segment, nanocarriers administered by intravitreal 
injection usually present a negative surface charge in order to avoid aggregation with the 
glycosaminoglycans present in the vitreous humor and a PEGylated surface to improve the 


















4. Site-specific nanocarriers-based polynucleotide delivery for the treatment of ocular 
pathologies 
The main diseases affecting the anterior and posterior segments of the eye will be discussed in 
the next sections as well as the nanocarriers developed for polynucleotide delivery to both 
segments. Tables 2 and 3 summarize some of the nanocarriers used for the delivery of 
polynucleotides aiming at the treatment of the discussed diseases. 
4.1. Nanomedicine approaches for the treatment of anterior segment ocular diseases 
There are two main target tissues in the anterior segment of the eye, the cornea and the 
conjunctiva. The cornea represents a key challenge for many drugs due to its highly organized 
multilayer epithelium and the presence of tight junctions that limit the permeation of drugs and 
polynucleotides (Ruponen and Urtti, 2015). Several viral vectors and naked-polynucleotide 
formulations have reached the clinical development phase for the treatment of ocular disorders, 
although none of them have been marketed yet. 
While the ocular delivery of polynucleotides has been achieved by physical means, such as 
electroporation (Blair‐Parks et al., 2002; Hao et al., 2009), iontophoresis (Berdugo et al., 
2003; Hao et al., 2009), gene gun (Tanelian et al., 1997; Zhang et al., 2002) and sonophoresis 
(Yamashita et al., 2007), the use of nanocarriers offers specific advantages, such as (i) their 
nanometric size and components properties may allow their transport in the conjunctival and 
corneal epithelium (Amrite and Kompella, 2005), (ii) they may provide a sustained delivery of 
polynucleotides in vivo (Cohen et al., 2000; dos Santos et al., 2006a; Khan et al., 2004) and, (iii) 
they may target the cornea, the conjunctiva or both (de la Fuente et al., 2008a; de la Fuente et 
al., 2008b). 
The most prevalent pharmacological ocular conditions in the anterior segment are DES, ocular 
inflammation (i.e. keratitis, allergic conjunctivitis, anterior uveitis), corneal wounds and, corneal 
NV. 
Dry eye syndrome 
DES is a multifactorial ocular pathology characterized by inflammation, pain and ocular 
discomfort due to insufficient tear secretion, excessive evaporation and alteration in the 
composition of the tear film (Pañeda et al., 2012). Current therapies for treating dry eye include 
drug-free artificial tears and nanosystems such as drug-free cationic nanoemulsions and 
cyclosporine A loaded nanoemulsions. As an alternative, polynucleotides have been proposed 
for the treatment of severe dry-eye associated to a deficiency of mucus glycoproteins, such as 
















et al. (2013) developed cationized gelatin-based nanoparticles to deliver a plasmid encoding a 
modified MUC5AC protein (pMUC5AC). This nanoformulation was instilled to a dry eye 
mouse model and the result of the treatment was a reduction in ocular inflammation 
accompanied by an improved tear production (Contreras-Ruiz et al., 2013).  
Keratitis, conjunctivitis, anterior uveitis 
These are diseases related to inflammation in the cornea, conjunctiva and the anterior uvea, 
respectively. The most common treatment strategies for these types of infections are 
antimicrobial ophthalmic solutions in the form of eye drops containing different drugs (e.g. anti-
histamines, non-steroidal anti-inflammatory drugs, antibiotics or corticosteroids). 
Polynucleotide-based therapies have also been considered as an alternative for the treatment of 
severe infectious and inflammatory processes. For example, stromal keratitis and angiogenesis 
induced by herpes simplex virus-I (HSV) in mice have been reported to be significantly reduced 
by intravenous injection of cationic polyplexes of PEG-PEI-RGD and anti-VEGF siRNA (Kim 
et al., 2004a). In a different study, PEI-siRNA complexes targeting the HSV-1 infected-cell 
polypeptide 4 gene were evaluated on a mouse model of herpes simplex keratitis. Following 
topical administration, the said complexes were found to inhibit HSV-I replication in vivo for 96 
h (Li et al., 2014).  
Corneal neovascularization  
Corneal NV is a pathological event that occurs associated with many ocular diseases that can 
cause blindness. Corneal NV means the formation of blood vessels within the transparent 
avascular tissue due to inflammation, infection and hypoxia, among other reasons. The available 
treatments include topical corticosteroids and non-steroidal anti-inflammatory eye drops and 
anti-VEGF-A compounds, such as bevacizumab, which were found to have limited clinical 
efficacy and negative side effects. Based on the critical role that angiogenesis plays in ocular 
neovascularization diseases, attempts have been made to attack these diseases using new anti-
VEGF polynucleotide therapies (targeting VEGF or its receptors). PLGA nanoparticles loaded 
with a plasmid containing a small hairpin RNA (shRNA) expression cassette against VEGF-A 
(pSEC.shRNA.VEGF-A) were injected into the corneal stroma in a corneal NV mice model. 
The plasmid-loaded nanoparticles were found to be effective in reducing the corneal expression 
of VEGF-A (Qazi et al., 2012). In another study, human serum albumin (HSA) nanoparticles 
encapsulating a plasmid (pCMV.Flt23K) were also injected into the cornea of mice and tested 
for their efficacy against corneal NV (Jani et al., 2007). The results showed that HSA 
nanoparticles provided a 40% reduction corneal NV after 5 weeks of treatment. A faster 
















containing the VEGFR1 plasmid (sflt-1). In this case, at seven days post-injection the corneal 
neovascularized area was reduced by 45% (Iriyama et al., 2011).  
In summary, only a few studies, which are summarized in Table 2, have disclosed the efficacy 
of synthetic nanocarriers for the treatment of eye-surface diseases either following topical 
instillation or intra-cornea/conjunctival injection. Nonetheless, and despite their ability to 
improve the retention time of polynucleotides in the ocular surface and transfect tissues, i.e. 
cornea and conjunctiva, their efficiency is difficult to judge. In fact, the in vivo studies reported 
so far do not provide a comparison of these new polynucleotides therapies with the currently 
available treatments.  
 
Table 2. Polynucleotide-loaded nanomedicines for the treatment of diseases affecting the 
anterior segment of the eye. 
 
4.2. Nanomedicine approaches for the treatment of back of the eye diseases  
Diseases affecting the retina can potentially be treated with polynucleotides-based therapies. 
The retina is a photosensitive tissue composed of three main layers or cell types. The retinal 
pigmented epithelium is in the outermost layer followed by the photoreceptors (cones and rods), 
and the retinal ganglion cells in the innermost layer. Defects in these cell layers can lead to 
AMD (retinal pigmented epithelium and photoreceptors), retinitis pigmentosa, Leber’s 
congenital amaurosis (LCA) (photoreceptors), glaucoma and optic neuropathy (retinal ganglion 
cells). According to the WHO, among the diseases affecting the posterior segment of the eye, 
glaucoma and AMD are the main causes for blindness. 
Subretinal injection is the most effective way to deliver drugs to the photoreceptors and RPE 
layer of the retina. Additionally, drugs can be injected into the vitreous humor through IVT 
injection that is less invasive and allows for a broader and more uniform transduction of the 
retina. Despite their efficacy, these methods are invasive and not acceptable when there is the 
need for frequent intraocular administrations. Repeated injections may lead to undesired side 
effects like high risk of infections, cataract development, vitreous hemorrhage and even retinal 
detachment and endophthalmitis that can potentially cause vision loss. Besides the risks of 
repeated injections, the poor stability of polynucleotides in biological fluids and their short 
vitreal half-life urges the need of developing carriers able to protect and deliver them in a 
specific, efficient and sustained way.  
As summarized in Table 3, several types of nanocarriers have been used to deliver 
















choroid, macula, and retina) or cell types (i.e. RGC, photoreceptors, and RPE) of this eye 
segment, expressing mutations responsible for diseases like AMD, glaucoma, CNV and X-
linked juvenile retinoschisis (XLRS), among others. These potential nanomedicines have been 
injected into the subretinal space or the vitreous humor. In this sense, it has been reported that 
positively charged particles may aggregate upon interaction with components present in these 
compartments, i.e. HA and GAGs, and this aggregation would ultimately hamper their cellular 
uptake (Peeters et al., 2005; Pitkänen et al., 2003). However, the vitreous humor can also act as 
a reservoir where the carriers can gradually release the compound of interest  to yield a 
sustained delivery of drugs to the retina (Bourges et al., 2003). 
Glaucoma  
Glaucoma is characterized by the progressive damage of the optic nerve leading to retinal 
ganglion cells death and permanent vision loss. According to the WHO, glaucoma is the second 
cause of vision loss worldwide after cataracts, being responsible for 8% of all blindness cases 
(Pascolini and Mariotti, 2011). Factors like local ischaemia-hypoxia, excessive stimulation of 
the glutamatergic system, alterations in glial cells, aberrant immunity and mainly high 
intraocular pressure (IOP) seem to contribute to glaucoma (Weinreb and Khaw, 2004). 
The current standard treatment for glaucoma involves medication to lower IOP levels by means 
of either diminishing aqueous humor production (beta blockers) or improving its drainage 
(prostaglandin analogs). These treatments are chronic and they often suffer from limited patient 
compliance. In addition, the side effects associated to systemic absorption are no negligible. 
Therefore, there is a clear need for advanced treatments and delivery technologies. 
In vivo studies of nanocarriers loaded with different drugs (e.g. timolol, brimonidine tartrate, 
pilocarpine) have shown promising results with increased bioavailability, prolonged retention 
time and sustained drug delivery in addition to minimizing systemic absorption of the associated 
drugs (Reimondez-Troitiño et al. 2015). Along the same line, a number of patents on 
ophthalmic nanoformulations such as nanoemulsions (Carli et al., 2013), and contact lenses 
delivering nanoemulsions (Chauhan and Gulsen, 2012), have been recently issued.  
Therapies based on polynucleotides could improve the commercially available anti-glaucoma 
treatments. Trabecular meshwork, ciliary epithelium and muscle and ganglion cell layer are 
some examples of target tissues for polynucleotide-based glaucoma therapy. However, research 
in this line is in a very early stage and has mainly made use of naked polynucleotides or viral 
vectors administered topically or as IVT and subretinal injections.  
The studies reported until now to contribute to the development of polynucleotide-based 
nanomedicines for the treatment of glaucoma have used model polynucleotides associated to 
















liposomes loaded with pDNA encoding β-Gal through topical instillation. In vivo data in rats 
showed gene β-Gal expression for up to a month in conjunctival, corneal and retinal ganglion 
cells after administration of N-(alpha-trimethylammonioacetyl)-didodecyl-D-glutamate 
(TMAG) and DC-cholesterol liposomes. A different approach consisted of liposomes with a 
viral envelope-coating of inactivated hemagglutinating virus of Japan HVJ (Sendai virus) 
(Hangai et al., 1996; Hangai et al., 1998a, b), which was supposed to allow the fusion of the 
liposomes with the cell membrane and deliver the encapsulated nucleotide into the cytoplasm. 
These liposomes were loaded with LacZ pDNA and a high-mobility group 1 (HMG1) 
nonhistone nuclear protein, which guides the pDNA into the nucleus. The in vivo results 
following intravitreal and subretinal injections of these formulations to rat and mice  presented 
LacZ expression in the photoreceptors for more than 30 days (Hangai et al., 1996). Moreover, 
these liposomes encapsulating FITC-labeled phosphorothioate oligonucleotides were injected 
into the anterior chamber of rats and monkeys. Fluorescence was detected in the trabecular 
meshwork of monkeys and in the iris and ciliary body of rats lasting as long as 7 and 14 days, 
respectively (Hangai et al., 1998b).  
Johnson et al. (Johnson et al., 2008) synthesized what they called a “peptide for ocular delivery 
(POD), containing specific aminoacids (GGG(ARKKAAKA)4), which theoretically endowed 
the peptide with cell penetrating properties, and used it for the delivery of pDNA encoding a red 
fluorescent protein (pCAGRFP) and siRNA to the eye. After topical instillation to mice, the 
pDNA-POD complexes were found to penetrate the corneal epithelium, sclera, choroid and even 
the optic nerve. The same nanocomplexes were also found to enter and deliver the associated 
siRNA in the GCL and RPE, following subretinal and IVT injection, respectively. A different 
formulation tested in vivo was the one combining pDNA with surfactant gemini and “helper” 
lipids DOPE and DOPE:1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOPE:DPPC). After 
topical application, these nanoparticles were found in the limbus, iris and conjunctiva for 48 h 
and, following IVT injection they were localized within the nerve fiber and GCL of the retina 
(Alqawlaq et al., 2014). 
Among the presented approaches only model polynucleotides and healthy animal models were 
used, thus no therapeutic effect or comparison with current treatments has been reported.  
Age-related macular degeneration 
AMD is the leading cause of irreversible blindness in people over 60 years old and it is 
predicted to affect about 196 million people worldwide by 2020 (Wong et al., 2014). This 
multifactorial disease leads to a progressive degeneration of photoreceptors in the central retina 
that can result in blindness. There are two forms of AMD, the “dry” and “wet” AMD. Wet 
















protein VEGF, which affects the central part of the retina, while dry AMD or nonexudative 
form is characterized by RPE cell death and consequent photoreceptor degeneration (Pañeda et 
al., 2012). Currently, AMD has no cure but there are some FDA approved treatments especially 
for the wet form like pegaptanib (Macugen

) an anti-VEGF aptamer, ranibizumab (Lucentis
®
) 
an antibody fragment, and aflibercept (Eylea

) a recombinant fusion protein, which is quickly 
becoming the gold standard treatment. Bevacizumab (Avastin

) is a monoclonal antibody which 
has also been used as an off-label treatment.  
With the idea of exploring new treatments for AMD, different pDNAs have been associated to 
different polymers originating nanoparticles and nanocomplexes of various compositions. For 
example, HSA has been found to be able to condense DNA and protect it from degradation 
(Langer et al., 2003; Mo et al., 2007). A plasmid encoding the Cu and Zn superoxide dismutase 
gene 1 (SOD1), a gene whose deficiency is associated with CNV and RPE dysfunction, was 
complexed with HSA and injected intravitreally to mice. Unfortunately, in vivo results revealed 
that protein expression was only detected for up to 2 days after IVT injection (Mo et al., 2007).  
In another study, PLGA nanoparticles were used to deliver a shRNA-expressing pDNA 
targeting hypoxia-inducible factor-1α (HIF-1α), which regulates the transcription of pro-
angiogenic factors like VEGF (Zhang et al., 2010). The in vivo results obtained following IVT 
injection to a laser-induced CNV rat model showed a decreased of VEGF expression and a 
reduction on the extent of NV.  
A different strategy involving the intravenous administration of PLGA nanoparticles 
functionalized with an RGD peptide, a ligand of integrin receptors, has been evaluated in mice 
and also primates. The results indicated that the said nanoparticles loaded with the plasmid 
pFlt23k.NR were able to get into the retina lesion, promote the plasmid expression for up to 6 
weeks and lower the CNV (Luo et al., 2013). In another study, the intravenous administration of 
anti-VEGF plasmid-loaded PLGA nanoparticles, functionalized with RGD and transferrin 
peptides, led to a high gene expression in RPE, and the subsequent inhibition of CNV (Singh et 
al., 2009). These positive results obtained following intravenous administration are surprising if 
we take into account the blood-retinal barrier that considerably limits access to the retina. In our 
understanding, a high dose will be required when using this modality of administration with the 
potential undesired off-target effects. Recently, Lajunen and co-workers (Lajunen et al., 2014) 
demonstrated that transferrin-decorated liposomes were able to reach the RPE by topical 
instillation in Sprague Dawley rats, thus avoiding the possible undesired side-effects associated 
with IVT and intravenous administrations. 
PEGylated liposomes containing protamine sulfate (PS) and HA loaded with a siRNA targeting 
















CNV. This system was able to protect the loaded siRNA and decrease the CNV area (Liu et al., 
2011).  
Dendrimers have also been tested as polynucleotide carriers in CNV animal models and could 
be considered as potential strategies for AMD treatment (Marano et al., 2004; Wimmer et al., 
2002). For example, Marano et al. (2004) developed different lipid-lysine dendrimers that led to 
a significant reduction in VEGF expression levels and were able to significantly inhibit CNV in 
a mice model. A long-term study using the laser-induced CNV mice model revealed that a 
single IVT injection of dendrimers loaded with ODN-1 inhibited up to 95% the development of 
CNV in rats and the response lasted for up to six months. This system was able to penetrate 
through all the retinal cell layers up to the RPE (Marano et al., 2005). 
 
Finally, the cationic nanoemulsions originally developed by Benita’s group (Hagigit et al., 
2010; Hagigit et al., 2012; Hagigit et al., 2008) and containing DOTAP were used to deliver a 
17-mer partially phosphorothioated ODN directed to the VEGF KDR receptor. This cationic 
nanoemulsion was administered by topical instillation and IVT injection and the results showed 
that, as expected, only the injected nanoparticles were able to reach the inner nuclear layer 
(INL) of the retina maintaining therapeutic levels for about 72 h after injection. (Hagigit et al., 
2010). 
Retinitis pigmentosa 
This disease affects one in 3,500 to 5,000 people worldwide and can be inherited as autosomal 
recessive (50-60%), autosomal dominant (30-40%) or X-linked (5-15%). RP can be the result of 
mutations in more than 60 genes being one of them rhodopsin, which accounts for 25% of 
autosomal dominant RP cases (Anasagasti et al., 2012). 
Based on the PEG stabilizing properties, the PEG-substituted lysine CK30-PEG was used for 
the formation of complexes with pDNA molecules of interest for RP treatment (Liu et al., 2003; 
Ziady et al., 2003). The use of this carrier allowed for the efficient delivery of a plasmid 
containing Rds cDNA and a rod opsin (MOP) promoter, and its expression in photoreceptors of 
a RP mouse model preventing cone degeneration. Gene expression was detected at least one 
month post-treatment (Cai et al., 2010). More recently, Han et al. used these particles to 
compare the efficacy between a genomic DNA (gDNA), which included introns from the 
rhodopsin gene, and a rhodopsin complementary DNA (cDNA). The introduction of specific 
genomic sequences improved the rhodopsin expression levels, delaying photoreceptor cells 
death and improving functionality up to eight months in a rhodopsin knockout (RKO) mouse 
model (Han et al., 2015).  
















XLRS affects one in 5,000 to 20,000 males who are diagnosed very early within their first years 
of life. The progression of this disease usually involves vitreous hemorrhage and retinal 
detachment that ultimately can lead to vision loss. Significant progress has been achieved in 
understanding the genetic and molecular mechanisms responsible for this disease. Currently, 
about 190 disease-causing mutations have been identified in the retinoschisis RS1 gene. The 
RS1 protein is secreted in the retina and it is responsible for maintaining the retina’s integrity 
(Molday et al., 2012). 
Gascón’s group developed a hybrid nanostructure consisting of a dextran-protamine sulphate–
pDNA complex (i.e. pCMS-EGFP or pCEP4-RS1) adsorbed onto the surface of solid lipid 
nanoparticles (Delgado et al., 2012). These plasmid-loaded particles were administered to rats 
through three different routes: IVT injection, subretinal injection and topical instillation. The 
results of these studies presented plasmid expression in the cornea after topical instillation, the 
nanocarriers were also able to transfect the RPE cells and photoreceptors by subretinal injection 
while by IVT administration gene expression was mainly detected in the ganglion cell layer. In 
a subsequent study, the same nanoparticles and a different kind containing HA instead of 
dextran (HA-protamine-pDNA-SLN) were administered by IVT and subretinal injections to 
C57BL/6 wild type and Rs1h-deficient mice models. Both carriers were able to transfect 
different layers of the retina, following both administration methods. However, when subretinal 
injection was used a higher amount of RS1 expression was detected in the photoreceptors and 
the expression was maintained for up to two months after injection it in GCL and INL. In 
addition, both carriers were able to lead to a partial recovery of the retina that consisted of 
mainly in a decreased loss of photoreceptors and an amelioration of the organization of retina 
layers (Apaolaza et al., 2015).  
Leber’s congenital amaurosis 
The prevalence of LCA is between 1 in 81,000 newborns (Stone, 2007). Fourteen mutated genes 
have already been identified and they are responsible for photoreceptor cell death at an early age 
causing blindness. About 6 % of LCA patients present mutations in RPE65 gene that encodes 
for all-trans-retinyl-ester hydrolase (den Hollander et al., 2008).  
PEG-Lysine complexed to a pEPI-eGFP and phRPE65, containing a scaffold matrix attachment 
region (S/MAR) and a macular dystrophy 2 promoter (VMD2), were subretinally administered 
to wild-type mice and to an RPE65-deficient LCA mice model, respectively (Koirala et al., 
2013) S/MAR inclusion was used considering its self-replication capacity residing inside cells 
for more than 100 generations (Piechaczek et al., 1999) and increase gene expression (Kim et 
al., 2004b; Klehr et al., 1991). The treatment led to higher DNA expression levels that lasted at 
















RPE cells expressed the gene, it still led to improvements in RPE65-deficient LCA disease that 
were noticed up to six months (Koirala et al., 2013).  
More recently, a different strategy combining DOTAP/DOPE/cholesterol liposomes with 
protamine-plasmid complexes, nuclear localization signaling and cell-penetrating transactivator 
of transcription (TAT) peptides was developed. These liposomes were administered by 
subretinal injection in a RPE65-associated blind mice model and the results showed the capacity 
of these nanocarriers to maintain gene expression for at least three months. Furthermore, in vivo 
results revealed that the treatment led to blindness correction (Rajala et al., 2014). 
Stargardt’s disease  
This autosomal recessive disease has no cure yet and it is the most common inherited juvenile 
macular degeneration affecting one in 8,000-10,000 people worldwide. Stargardt’s disease 
causes problems to adapt to darkness and a progressive and irreversible loss of central vision. 
The disease is caused by mutations in the ABCA4 gene that encodes a protein of the ABC lipid 
transporter family (Allikmets et al., 1997). Hundreds of disease-causing mutations have been 
identified in this gene that can lead to Stardardt’s or to cone-rod dystrophy and several forms of 
autosomal recessive RP (Cremers et al., 1998). To the extent of our knowledge, only PEG-
Lysine complexed to pDNA have been assessed for this disease and gene expression was 
detected for about eight months improving mice’s recovery of dark adaptation (Han et al., 
2012).  
Diabetic retinopathy  
This ocular pathology is the most frequent complication of diabetes mellitus, a disease that 
according to the WHO affects more than 422 million individuals around the world. Diabetic 
retinopathy which affects more than 93 million people results from vascular abnormalities 
causing glial dysfunction and death of retinal neurons, and ultimately, blindness (Yau et al., 




 are some of the 
FDA approved treatments for this disease. As an alternative, different siRNA therapies, such as 
those targeting the connective tissue growth factor (CTGF) (Winkler et al., 2012), VEGF (Jiang 
et al., 2009), fibronectin, collagen and laminin (Oshitari et al., 2005), HIF-1α (Jiang et al., 
2009), or hypoxia-inducible gene RTP801 (Nguyen et al., 2012) have been proposed. However, 
these siRNAs have not been used in association with nanocarriers so far. 
Different approaches making use of anti-angiogenic microRNAs (Mitra et al., 2016) and 
plasminogen fragments (Park et al., 2009) associated to PEG-Lysine have also been explored. 
These nanocomplexes were intravitreally injected in a mouse model for late-onset diabetic 
retinopathy. A single administration reduced the expression of VEGFR-2, suppressing 
















PLGA nanoparticles loaded with a plasminogen fragment Kringle 5 (K5) plasmid were 
administered by IVT injection in oxygen-induced retinopathy (OIR) and streptozotocin-induced 
diabetic mice models. Similarly, a single injection led to a significant reduction of retinal 
vascular leakage and attenuated VEGF over-expression and retinal NV for at least one month 
(Park et al., 2009). 
Despite the ability of synthetic nanocarriers for ocular polynucleotide delivery and all the 
potential advantages and the promising results observed in animal models, their delivery 
efficiency is still low. On the other hand, the majority of the clinical trials using polynucleotides 
for ocular diseases have used naked polynucleotide treatments and about 20% have combined 
them with viral vectors, especially AAVs,. These clinical trials have been oriented to the 
treatment of macular degeneration, LCA and Leber´s hereditary optic atrophy. Despite of this, it 
should be recognized that major advances in ocular polynucleotide-based therapies have already 
been achieved and that this field is now opening opportunities for future developmental 
programs. The main approaches used to improve non-viral carriers performance in the treatment 
of the previously discussed diseases affecting both anterior and posterior segments are 
summarized in Fig. 5 A and B, respectively.  
 
Table 3. Polynucleotide-loaded nanocarriers for the treatment of conditions affecting the 
posterior segment of the eye. 
 
5. Translational aspects of ocular delivery of polynucleotides  
Despite the multiple reports centered on the benefits of nanotechnology for treating ophthalmic 
conditions it is surprising that only a small number of these products have obtained marketing 
authorization. As indicated in section 3, besides a variety of emulsions and liposomes, which are 
over-the-counter products for the treatment of DES, there are nanoemulsions containing specific 




) and difluprednate (Durezol
®
) for the 
treatment of ocular inflammation, and liposomes containing verteporfin (Visudyne
®
) and the 
PEGylated anti-VEGF aptamer, pegaptanib (Macugen
®
), both for the treatment of AMD. The 
majority of these products are emulsions composed of well-known oils (castor oil or medium-
chain triglycerides oil), emulsifiers (polysorbate 80, pemulen, poloxamer 188, tyloxapol or 
cetalkonium chloride) and excipients to maintain tonicity and pH. However, the application of 
more sophisticated technologies for the development of oligonucleotide-based nanomedicines is 
associated to significant challenges as highlighted below. 
The term nanomedicine includes an ample range of products with enormous variations in size, 
















classifications of these products difficult to establish from the regulatory standpoint, thus 
complicating the generation of appropriate regulatory guidance. Both, the FDA and the EMA, 
however, consider that the development of a product that falls within the definition of 
nanotechnology may require special attention in terms of toxicity and safety.  
Market authorization of pharmaceuticals requires a full physical and chemical characterization 
of the drug. The increasing complexity of nanomedicines indicates that characterization has 
most likely to be tailored for the specific product in development. The initial phases of product 
development may require a thorough characterization to select the specific tests that will 
subsequently be used to release batches and test the quality of the final product. Therefore, as 
with other medicinal products, it is important to identify the critical quality attributes (CQAs) 
that maintain a direct relationship with products quality, efficacy and toxicity; these CQAs 
should be the basis for the product’s quality control throughout its lifecycle. CQAs for 
ophthalmic nanomedicines may include aspects related to nanotechnology such as particle size, 
size distribution, surface charge, hydrophilicity; but also attributes related to pharmaceuticals, 
such as purity, stability, sterility, and manufacture controls. Among the ophthalmic products 
approved so far, only the cationic nanoemulsion containing cyclosporine A specifically lists 
CQA related to nanotechnology: particle size and zeta potential. This is important as it is well 
known that size has a direct impact on the biodistribution and clearance of the nanomedicine. 
For instance, subconjunctival administration of fluorescent polystyrene nanoparticles has shown 
that 20 nm nanoparticles exhibit a rapid clearance from ocular and periocular tissues while 200 
nm nanoparticles made of the same material are retained in the eye for a period of two months 
(Amrite and Kompella, 2005). It should also be considered that the nanomaterial administered 
to the eye can aggregate, thereby influencing the in vivo behavior of the nanomedicines.  
On the other hand, although small scale manufacturing of different types of nanomedicines in 
research laboratories is fairly common, with the exception of nanoemulsions, the experience in 
large-scale manufacturing is still limited. Large-scale manufacturing requires standardization 
and manufacturing under Good Manufacturing Practices (GMP). Factors affected by the scale-
up include changes in particle size, drug loading, quality and quantity of impurities, structural 
alterations, among others. In particular, for oligonucleotides changes in manufacturing 
processes may lead to decreased stability or even degradation of the product, as a consequence, 
a very well controlled small-scale process may turn out to be unreliable or non-reproducible at a 
larger scale if the process has not been efficiently controlled during the scale-up. For multi-step 
processes it is usually useful to establish mid-process controls that can inform of the quality of 
the intermediate products in order to better control the process as a whole.  
An additional specific requirement of ocular pharmaceuticals is sterility. Many materials used to 
















irradiations or autoclaving. For small or malleable particles double filtration may be an option 
for sterilizing the final product but for bigger rigid particles aseptic manufacturing may be the 
only option.  
Many nanocarriers are specifically designed to improve delivery of the active ingredient, thus it 
is expected that biodistribution of the nanomedicine and its unformulated counterpart should be 
significantly different. In fact, for ocular administration, it is crucial to determine whether the 
formulation changes the ability of the drug to enter systemic circulation. Many approaches to 
develop nanomedicines for eye conditions seek precisely this aim; to reduce the amount of 
compound that enters systemic circulation reducing the potential systemic side or off-target 
effects of the drug. One of the main challenges of pharmacokinetic (PK) studies of 
nanomedicines is to address the fate of the free drug following administration of a 
nanomedicine. For efficacy assessment the amount of free drug reaching the intended site 
should be measured. On the other hand, the distribution of the complete nanomedicine and its 
fate following delivery should be studied in order to address eventual toxicities associated to the 
nanocarrier. For larger molecules, such as oligonucleotides specific methods used to assess the 
free drug should be used to quantify the amount of drug reaching the target site. Subtle 
variations in the characteristics of nanomedicines may result in altered patterns of 
biodistribution; therefore it is generally expected that PK profiles of nanomedicines have greater 
variability than PK profiles obtained with unformulated drugs. In addition, for ocular 
pharmaceuticals administered in eye drops the percentage of entrapment, which is the amount of 
drug in one eye drop, is difficult to control further increasing the variability of the PK profiles. 
These inherent characteristics of nanomedicines for ophthalmic use should be taken into account 
when designing PK studies to avoid unnecessary duplication of experimental work. The surface 
characteristics of the nanomedicine have a strong impact on the absorption and distribution of 
the drug and can be modified by surface coatings in order to obtain particles with the desired 
characteristics. 
It is generally accepted that specific types of nanomedicines may raise concerns in terms of 
toxicity, but the general battery for assessing toxicity of drugs in a preclinical setting should be 
able to identify these toxic effects and their potential relation to dose. Knowledge about the 
differences in biodistribution between the unformulated drug and the nanomedicine are helpful 
to pinpoint possible target tissues for toxicity. Also, additional tests may be needed if 
components of the nanomedicine are known to have dose-limiting toxicities or if any of the 
components are not naturally degraded and excreted. Particular attention should be made on 
potential immunotoxic effects. These toxicities are not necessarily deduced from the 
unformulated drug as they may arise from specific interaction of the drug with other 
















biological fluids. The physical characteristics of the nanomedicines may also increase their 
potential to interact with biological components. In the particular case of the eye, interaction 
with melanin may alter the PK profile of the drug in the eye generating locally high 
concentration of the drug upon release from melanin (Agrahari et al., 2016). Formulations 
reaching the bloodstream may also potentially interact with components of the complement 
system or coagulation inducing side effects (Yousefi et al., 2014). The assessment of these 
toxicities is not necessarily straightforward as animal models are not necessarily good predictors 
of human immune systems. In these cases, in vitro tests with human cells can be used to 
complement animal studies.  
The production of nanosystems usually requires the use of surfactants. Surfactants lower the 
surface tension between the nanosystem and the dispersion liquid acting as stabilizing agents. 
Usually there is a correlation between the amount of surfactant used and the size of the 
nanoparticles, with low concentration of surfactant generally yielding smaller particles. 
Unfortunately, surfactants may cause ocular irritation when administered at high concentrations 
and need to be removed from the formulation or used in concentrations that are compatible with 
the ocular surface. For ophthalmic products this approaches are combined with the aim of 
reducing the amount of surfactants to concentrations that are tolerable by the eye without 
removing them completely as they usually act as penetration enhancers facilitating the entrance 
of compounds (Leonardi et al., 2014).  
Clinical translation of nanomedicines for ophthalmic conditions has different requirements 
depending on the indication and route of administration. Topical ocular eye drops are the 
preferred option for treating the anterior segment of the eye whereas nanodrugs for the back of 
the eye are usually developed to release drug over an extended period of time to reduce the 
frequency of administration. Nanomedicines that include oligonucleotides should protect them 
against degradation by nucleases. Human biological fluids contain higher concentration of 
nuclease activity than most animal models, therefore stability studies of the nanomedicine need 
to be complemented to assess the stability of the drug in humans (Martínez et al., 2014). In 
addition, ophthalmic nanomedicines need to comply with the general requirements for drugs 
administered by the ocular route. For topical forms parameters such as sterility, osmolality, 
antimicrobial agents, buffering, viscosity, pH, particulate matter and compatibility with 
packaging have to be considered. 
Finally, it should be mentioned that development of complex delivery systems for ophthalmic 
drugs is highly costly. As previously mentioned, the processes for developing nanomedicines 
may require additional data not generally required for small molecules. This, added to the 
insufficient regulatory framework and the potential complexity of the scale-up processes may 
















for the industry to design developmental plans where the size of the ophthalmic market 
outweighs the efforts and financial expenses associated to the development.  
Currently there are several advanced preclinical programs developing nanomedicines with small 
drugs for different ocular conditions. Most of these drugs are already commercialized and are 
being reformulated in order to improve their efficacy as well as to find new indications for 
them. Overall, the more advanced technologies include the production of nanoemulsions and 
liposomes. As these compounds reach the market it is expected that nanoformulations are also 
incorporated into the pipelines of more complex molecules such as oligonucleotides or peptides.  
 
6. Conclusions and future perspectives 
Although therapies involving polynucleotides for treating ocular diseases are in an early 
development stage, preliminary human clinical trials begin to show promising results. 
Currently, there are two FDA approved nucleic acid-based drugs for eye conditions: Vitravene

, 
an AS-ODN for cytomegalovirus-induced retinitis treatment in immunocompromised patients, 
and Macugen

 an aptamer designed to treat wet AMD. Curiously, this aptamer is PEGylated 
and, as such, maybe considered as a nanomedicine. In principle polynucleotide-based drugs do 
not comply with the best physicochemical properties to be used as effective drugs, however, 
their chemical modification and the development of easy to produce nanocarriers offer a great 
window of opportunity for the exploitation of these new therapies. Currently, several ocular 
diseases of the anterior and posterior segment of the eye such as glaucoma, AMD, ocular pain 
associated to dry eye and CNV are under gene-based clinical trials evaluation. Development of 
effective future ocular treatments will be a combination of understanding the diseases genetic 
basis as well as improving and developing long-term and nontoxic ocular drug delivery systems 
for both segments of the eye. It is believed that AS-ODN and RNA-based therapeutics 
(specially siRNA-based as it is a potent inhibitor of protein expression) will continue further 
development reaching the market in a reasonable time frame being the major task to achieve 
their nanosystems delivery along with investigating alternative routes of administration. 
If nanotechnology is successfully combined with polynucleotides, their delivery, the greatest 
hurdle holding these drugs from the clinic, could be overcome. The following years will tell if 
these combined approaches can be used in the treatment of severe ocular diseases that nowadays 
relay on painful, inconvenient and inefficacious treatments. Much effort will have to be put into 
place for the efficient delivery of the genetic material to targeted cells/tissues being one of the 
most challenging tasks to be accomplished by multidisciplinary research teams composed of 
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Table 1. Products under clinical development for both the anterior and posterior segments of the 
eye 































siRNA      
QPI-1007 
NAION  











RTP801 IVT Quark/Pfizer 
Completed 







Glaucoma β2 ADR Eye drop Sylentis 
Completed 




associated to DES 
TRPV1 Eye drop Sylentis 
Completed 




Wet AMD  
CTGF IVT Rxi 
Recruting 
Phase I/II 
AS-ODN      
GS-101 
(aganirsen) 
iCRVO Patients at 
Risk of Developing 
NVG 





























pDNA, plasmid DNA; siRNA, small interfering RNA; AS-ODN, antisense oligonucleotides; NAION, 
Non-arteritic anterior ischemic optic neuropathy; APACG, Primary angle closure glaucoma; AMD, Age-
related macular degeneration; DME, Diabetic macular edema; DES, Dry eye syndrome; iCRVO, 
Ischemic central retinal vein occlusion; NVG, Neovascular glaucoma; DR, Diabetic retinopathy; IPCV, 
Idiopathic polypoidal choroidal vasculopathy; GA, Geographic atrophy; MD, macular degeneration; JCR, 
Japanese Red Cedar pollen; Gp 100, glycoprotein 100; RTP801, hypoxia-inducible factor 1-responsive 
gene; β2 ADR, β2-adrenergic receptor; TRPV1, transient receptor potential vanilloid 1; CTGF, 
connective tissue growth factor; IRS-1, insulin receptor substrate-1; TGF-β2, transforming growth factor 























Phase II and 
Phase III 
Active  
Phase III  
Active  






























Table 2. Polynucleotide-loaded nanomedicines for the treatment of diseases affecting the 
anterior segment of the eye. 







Dry eye syndrome     
Gelatin 
nanoparticles 







Ruiz et al., 
2013) 












(Kim et al., 
2004b) 




(Li et al., 
2014) 





















40% reduction of 
Corneal NV after 
5 weeks 








45% reduction of 




PEG, polyethylene glycol; PEI, polyethyleneimine; RGD, arginine-glycine-aspartic acid; PLGA, 
poly(lactic-co-glycolic acid); HSA; human serum albumin, pMUC5AC, plasmid encoding the mucus 
glycoprotein MUC5AC; ICP4-siRNA, siRNA targeting the infected-cell polypeptide 4 gene of HSV-1; 
pSEC.shRNA.-VEGF-A, plasmid containing a small hairpin RNA expression cassette against vascular 
endothelial growth factor A; pCMV.Flt23K, plasmid encoding domains 2 and 3 of the Flt binding domain 
for VEGF; psflt-1, plasmid encoding soluble VEGF receptor 1; HSK, herpes simplex keratitis; Corneal 


















Table 3 Polynucleotide-loaded nanocarriers for the treatment of conditions affecting the 
posterior segment of the eye. 




Outcome (PK/PD) Ref. 




pCMV-β-Gal Eye drops Healthy 
rat 
β-Gal expression in 
conjunctiva, cornea and 











β-Gal expression in neural 














Fluorescence in trabecular 
meshwork for 7 










pDNA detected in retina’s 
nerve fiber and GCL 48h 
after IVT injection 
(Alqawlaq et 
al., 2014) 
Age-related macular degeneration 
HSA 
nanoparticles 





detected 2 days after 
injection but not after 7 
days 








expression and reduced 














Lowered CNV; improved 
40% mice’s vision 













47-73% reduced CNV 
area, 2 weeks after 
treatment 






IVT injection CNV 
mice 
model 
Inhibited by 95% the 









IVT injection CNV 
mice 
model 






















VEGF KDR IVT injection rabbits reached the retina’s INL al., 2010) 








Improved rhodopsin levels 
and improved 
photoreceptors 
functionality for 8 months 













Prevention of cone 
degeneration 
(Cai et al., 
2010) 



























Partial recovery of retina 
for 2 months 
(Apaolaza et 
al., 2015) 















Gene expression lasted for 
2.5 years in the healthy 
mice 
Improved the phenotype 


















Gene expression in RPE 
















Gene expression in the 
retina for 8 months 
Improved recovery of 
dark adaptation 













(Mitra et al., 
2016) 
PLGA pK5 IVT injection OIR 
mice 





















TMAG, N-(alpha-trimethylammonioacetyl)-didodecyl-D-glutamate; DC-cholesterol, 3-β[N-(N’,N’ 
imethylaminoethane)- carbamoyl] colesterol; HJV-AVE, inactivated hemagglutinating virus of Japan-
artificial viral envelope; HSA, human serum albumin; PLGA, poly(lactic-co-glycolic acid); RGD, 
arginine-glycine-aspartic acid; PS, protamine sulfate; HA, hyaluronic acid; SLN, solid lipid nanoparticles; 
DOTAP, 1,2-Dioleoyl-3- trimethylammonium propane; AOA, arginine octadecyl amide; DOPE, 1,2-
dioleoyl-3- hosphatidylethanolamine; NLS, peptide of nuclear localization signaling; TAT, cell-
penetrating transactivator of transcription; pCMV-β-Gal, plasmid containing cytomegalovirus pomoter 
and enconding β-galactosidase gene; pSOD, plasmid encoding superoxide dismutase gene; pshHIF-1α, 
plasmid containing a small hairpin RNA targeting the hypoxia-inducible factor 1α; AS-ODN, antisense 
oligonucleotides; VEGF, vascular endothelial growth factor; gDNA, genomic DNA; pEPI-EGFP, plasmid 
encoding a green fluorescent protein; S/MAR, scaffold matrix attachment region; VMD2, vitelliform 
macular dystrophy 2 promoter; pK5, Kringle 5 plasmid; pCAG-GFP_CMV-RS1, plasmid encoding both 
GFP and retinoschisin; IVT, intravitreal; CNV, choroidal neovascularization; RKO, rhodopsin knockout; 
OIR, oxygen-induced retinopathy; GCL, ganglion cell layer; RGC, retinal ganglion cells; GCL, ganglion 
cell layer; INL, inner nuclear layer; RPE, retinal pigmented epithelium 
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